Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Study to Determine Safety and Dose of NJH395 in Non-breast HER2+ Advanced Cancer

Phase 1

Completed

Conditions: NON-breast HER2+ Malignancies

Interventions: Drug: NJH395

First Posted Date: 2018-10-05

Last Posted Date: 2022-02-04

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 18

Registration Number: NCT03696771

Locations: 🇰🇷
Novartis Investigative Site, Seoul, Korea, Republic of
🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Evaluation of the Pharmacokinetics of Tropifexor in Subjects With Mild, Moderate, or Severe Hepatic Impairment Compared to Healthy Control Subjects

Phase 1

Completed

Conditions: Non-alcoholic Fatty Liver Disease

Interventions: Drug: LJN452

First Posted Date: 2018-09-24

Last Posted Date: 2020-12-14

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 42

Registration Number: NCT03681457

Locations: 🇺🇸
Novartis Investigative Site, Knoxville, Tennessee, United States

Study of Efficacy of Fevipiprant in Patients With Nasal Polyposis and Asthma

Phase 3

Completed

Conditions: Nasal Polyps

Interventions: Drug: Fevipiprant 150 mg
Drug: Fevipiprant 450 mg
Drug: Placebo

First Posted Date: 2018-09-21

Last Posted Date: 2021-10-11

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 98

Registration Number: NCT03681093

Locations: 🇵🇱
Novartis Investigative Site, Zawadzkie, Poland

Efficacy and Safety of Ribociclib in Pre- and Postmenopausal Chinese Women With HR Positive, HER2-negative, Advanced Breast Cancer.

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Drug: Ribociclib Placebo
Drug: Ribociclib
Drug: Letrozole
Drug: Goserelin

First Posted Date: 2018-09-14

Last Posted Date: 2025-05-28

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 327

Registration Number: NCT03671330

Locations: 🇨🇳
Novartis Investigative Site, Tianjin, China

Study to Assess the Long-term Safety, Tolerability, Efficacy of Secukinumab in Pediatric Patients of Age 6 to <18 Years, With Moderate to Severe Plaque Psoriasis

Phase 3

Completed

Conditions: Moderate to Severe Chronic Plaque-type Psoriasis

Interventions: Drug: secukinumab high dose
Drug: secukinumab low dose

First Posted Date: 2018-09-12

Last Posted Date: 2025-05-16

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 84

Registration Number: NCT03668613

Locations: 🇺🇸
Texas Derm and Laser Specialists ., San Antonio, Texas, United States
🇺🇸
First OC Dermatology, Fountain Valley, California, United States
🇪🇸
Novartis Investigative Site, Valencia, Spain

and more 1 locations

Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Kidney Transplant Recipients

Phase 2

Completed

Conditions: Kidney Transplant Rejection

Interventions: Drug: Tacrolimus - MMF - +/- corticosteroids
Biological: CFZ533 - MMF - CS

First Posted Date: 2018-09-10

Last Posted Date: 2022-06-13

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 418

Registration Number: NCT03663335

Locations: 🇬🇧
Novartis Investigative Site, Manchester, United Kingdom

Study the Efficacy and Safety of VAY736 and CFZ533 in SLE Patients

Phase 2

Active, not recruiting

Conditions: Systemic Lupus Erythematosus (SLE)

Interventions: Drug: VAY736
Drug: CFZ533
Drug: VAY736 Placebo
Drug: CFZ533 Placebo

First Posted Date: 2018-09-04

Last Posted Date: 2024-12-27

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 107

Registration Number: NCT03656562

Locations: 🇹🇭
Novartis Investigative Site, Bangkok, Thailand

Pharmacokinetics, Safety and Tolerability of Fevipiprant Delivered Via a Once Daily Chewable Tablet in Children Aged 6 to < 12 Years With Asthma

Phase 2

Terminated

Conditions: Asthma

Interventions: Drug: Fevipiprant

First Posted Date: 2018-08-28

Last Posted Date: 2021-10-11

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 11

Registration Number: NCT03650400

Locations: 🇺🇸
Novartis Investigative Site, San Antonio, Texas, United States

Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS

Phase 3

Active, not recruiting

Conditions: Relapsing Multiple Sclerosis

Interventions: Biological: Ofatumumab
Biological: Tetanus toxoid (TT) containing vaccine (Td, Tdap)
Biological: 13-valent pneumococcal conjugate vaccine (13-PCV)
Biological: 23-valent pneumococcal polysaccharide vaccine (23-PPV)
Biological: Seasonal Quadrivalent influenza vaccine
Biological: Keyhole limpet hemocyanin (KLH) neo-antigen

First Posted Date: 2018-08-28

Last Posted Date: 2025-06-04

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 1882

Registration Number: NCT03650114

Locations: 🇺🇸
BG Neurology, Spartanburg, South Carolina, United States
🇺🇸
Upstate Clinical Trials LLC, Spartanburg, South Carolina, United States
🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States

and more 82 locations

Study of Capmatinib and Spartalizumab Combination Therapy vs Docetaxel in Non-small Cell Lung Cancer

Phase 2

Completed

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Drug: Capmatinib
Drug: Docetaxel
Drug: Spartalizumab

First Posted Date: 2018-08-27

Last Posted Date: 2022-01-24

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 18

Registration Number: NCT03647488

Locations: 🇺🇸
Highlands Oncology Group, Fayetteville, Arkansas, United States
🇪🇸
Novartis Investigative Site, Madrid, Spain

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy